Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 49.1% in September

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 2,900 shares, a decrease of 49.1% from the August 31st total of 5,700 shares. Based on an average trading volume of 11,400 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 11,400 shares, the days-to-cover ratio is presently 0.3 days.

Global X Genomics & Biotechnology ETF Stock Up 1.7%

NASDAQ GNOM opened at $41.19 on Monday. Global X Genomics & Biotechnology ETF has a twelve month low of $27.20 and a twelve month high of $44.52. The firm has a market cap of $50.25 million, a price-to-earnings ratio of -17.60 and a beta of 1.03. The business has a 50-day moving average price of $36.87 and a 200-day moving average price of $34.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Oxinas Partners Wealth Management LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 12.1% during the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after buying an additional 1,751 shares during the period. Comprehensive Money Management Services LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 10.9% in the first quarter. Comprehensive Money Management Services LLC now owns 20,355 shares of the company’s stock worth $162,000 after acquiring an additional 2,000 shares in the last quarter. Atria Investments Inc grew its stake in shares of Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after acquiring an additional 2,073 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after acquiring an additional 2,184 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 18.5% during the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock worth $125,000 after purchasing an additional 2,329 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.